Cover Image
Market Research Report

Global Migraine Drugs Market (by Mode of Administration, Treatment Class & Regions): Insights and Forecast with Potential Impact of COVID-19 (2020-2024)

Published by Koncept Analytics Product code 960378
Published Content info 107 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Migraine Drugs Market (by Mode of Administration, Treatment Class & Regions): Insights and Forecast with Potential Impact of COVID-19 (2020-2024)
Published: September 14, 2020 Content info: 107 Pages
Description

The global migraine market is expected to reach US$5.10 billion in 2024, growing at a CAGR of 3.7%, for the duration spanning 2020-2024. The factors such as growing female population, increasing cigarette consumption, increasing pharmaceutical R&D expenditures, accelerating economic growth, increasing healthcare spending, increasing stress levels, unmet medical needs and prevalence of migraine at high rates would drive the growth of the market. However, the market growth would be challenged by adverse effect of drugs, lack of proper diagnosis, increased preferences for alternative options, regulatory challenges and high cost associated. A few notable trends include, growth in pharmaceutical & biotech merger & acquisition, progressing CGRP targeting drug pipeline, branded acute treatment for episodic migraine, growing awareness regarding migraine and its therapeutics and development of additional migraine therapeutics.

The global migraine market holds a lucrative growth opportunity for the coming future due to the high prevalence rate of migraine among people. Migraine market is expected to witness the advent of first-in-class novel migraine therapeutics, especially meant for patients who are unresponsive to triptans or ones at risk of cardiovascular disorders. A considerable amount of funds are being invested in the research and development of new migraine drugs, in order to make such therapeutics available in market. A number of drugs are under late stage clinical process and some therapeutics are registered for the FDA approval. Launches of new migraines drugs would thereby help the migraine market to grow globally in coming years.

The fastest growing regional market is North America, due to the presence of well established healthcare infrastructure as well as major pharmaceutical players. Increased retail sales of triptans and ergot alkaloids, demanded by the people with acute migraine conditions for the abortive purpose, helped the market to grow at a considerable pace in the region. Europe and Asia Pacific also secured considerable shares in the migraine market, owing to the high prevalence rate of migraine, along with the increased programmes of collaboration and partnership in the pharmaceutical sector. Further, the sudden outbreak of COVID-19, would trigger the stress levels among people, due to the implementation of the lockdown measures, which would elevate the risk of migraine among them and thereby is expected to accelerate the growth of the global migraine market in coming years.

Scope of the report:

  • The report provides a comprehensive analysis of the global monoclonal antibodies market.
  • The major regional markets (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa) have been analyzed.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (Johnson & Johnson, Novartis AG, Merck & Co., AbbVie Inc., Bristol-Myer Squibb and Amgen AG) are also presented in detail.

Key Target Audience:

  • Monoclonal Antibodies Manufacturers
  • Pharmaceuticals and Biopharmaceutical Firms
  • End Users (Hospitals and Research Institutes)
  • Investment Banks
  • Healthcare and Medical Consultants
  • Government Bodies & Regulating Authorities
Table of Contents

Table of Contents

1. Overview

  • 1.1 Migraine
  • 1.2 Types of Migraine
  • 1.3 Stages of Migraine
  • 1.4 Diagnosis Procedures
  • 1.5 Migraine Treatment
  • 1.6 CGRP - A New Era of Migraine Treatment

2. Impact of COVID-19

  • 2.1 Rise in Stress Level
  • 2.2 Growth in Government Spending on Healthcare
  • 2.3 Increase in Alcohol Consumption
  • 2.4 Impact of Excessive Use of Hand Sanitizers

3. Global Market Analysis

  • 3.1 Global Migraine Drugs Market by Value
  • 3.2 Global Migraine Drugs Market Forecast by Value
  • 3.3 Global Migraine Drugs Market by Mode of Administration
    • 3.3.1 Global Oral Migraine Drugs Market by Value
    • 3.3.2 Global Oral Migraine Drugs Market Forecast by Value
    • 3.3.3 Global Injectable Migraine Drugs Market by Value
    • 3.3.4 Global Injectable Migraine Drugs Market Forecast by Value
  • 3.4 Global Migraine Drugs Market by Treatment Class
    • 3.4.1 Global Abortive Migraine Drugs Market by Value
    • 3.4.2 Global Abortive Migraine Drugs Market Forecast by Value
    • 3.4.3 Global Preventative Migraine Drugs Market by Value
    • 3.4.4 Global Preventative Migraine Drugs Market Forecast by Value
  • 3.5 Global Migraine Drugs Market by Regions

4. Regional Market

  • 4.1 North America
    • 4.1.1 North America Migraine Drugs Market by Value
    • 4.1.2 North America Migraine Drugs Market Forecast by Value
    • 4.1.3 North America Migraine Drugs Market by Region
    • 4.1.4 The U.S. Migraine Drugs Market by Value
    • 4.1.5 The U.S. Migraine Drugs Market Forecast by Value
  • 4.2 Europe
    • 4.2.1 Europe Migraine Drugs Market by Value
    • 4.2.2 Europe Migraine Drugs Market Forecast by Value
  • 4.3 Asia Pacific
    • 4.3.1 Asia Pacific Migraine Drugs Market by Value
    • 4.3.2 Asia Pacific Migraine Drugs Market Forecast by Value
  • 4.4 ROW
    • 4.4.1 ROW Migraine Drugs Market by Value
    • 4.4.2 ROW Migraine Drugs Market Forecast by Value

5. Market Dynamics

  • 5.1 Growth Drivers
    • 5.1.1 Growing Female Population
    • 5.1.2 Increasing Cigarette Consumption
    • 5.1.3 Increasing Pharmaceutical R&D Spending
    • 5.1.4 Accelerating Economic Growth
    • 5.1.5 Increasing Healthcare Spending
    • 5.1.6 Increasing Stress Levels
    • 5.1.7 Unmet Medical Needs
    • 5.1.8 Prevalence of Migraine at High Rate
  • 5.2 Key Trends and Developments
    • 5.2.1 Growth in Pharmaceutical and Biotech Merger & Acquisition
    • 5.2.2 Progressing CGRP - Targeting Drug Pipeline
    • 5.2.3 Branded Acute Treatment for Episodic Migraine
    • 5.2.4 Growing Awareness about Migraine and its Treatment
    • 5.2.5 Development of Additional Migraine Therapeutics
  • 5.3 Challenges
    • 5.3.1 Adverse Effects of Drugs
    • 5.3.2 Lack of Proper Diagnosis
    • 5.3.3 Increased Preference for Alternative Therapies
    • 5.3.4 Regulatory Challenges
    • 5.3.5 High Cost Associated

6. Competitive Landscape

  • 6.1 Global Market
    • 6.1.1 Key Players - Revenue Comparison
    • 6.1.2 Key Players - R&D Expenditure Comparison
    • 6.1.3 Key Players - Market Capitalization Comparison
  • 6.2 The U.S. Market
    • 6.2.1 Key Players - The U.S. CGRP Drugs for Episodic Migraine Market Penetration Forecast
    • 6.2.2 Key Players - The U.S. CGRP Drugs for Chronic Migraine Market Share Forecast

7. Company Profiles

  • 7.1 Novartis AG
    • 7.1.1 Business Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Business Strategies
  • 7.2 Merck and Co.
    • 7.2.1 Business Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Business Strategies
  • 7.3 Amgen AG
    • 7.3.1 Business Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Business Strategies
  • 7.4 Eli Lilly and Company
    • 7.4.1 Business Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Business Strategies
  • 7.5 Teva Pharmaceuticals
    • 7.5.1 Business Overview
    • 7.5.2 Financial Overview
    • 7.5.3 Business Strategies
  • 7.6 Lundbeck
    • 7.6.1 Business Overview
    • 7.6.2 Financial Overview
    • 7.6.3 Business Strategies

List of Figures

  • Migraine
  • Diagnosis Procedures
  • Global Government Share on Health Spending (2019-2024)
  • Global Alcoholic Beverage Consumption (2017-2021)
  • Global Migraine Drugs Market by Value (2015-2019)
  • Global Migraine Drugs Market Forecast by Value (2020-2024)
  • Global Migraine Drugs Market by Mode of Administration (2019)
  • Global Oral Migraine Drugs Market by Value (2015-2019)
  • Global Oral Migraine Drugs Market Forecast by Value (2020-2024)
  • Global Injectable Migraine Drugs Market by Value (2015-2019)
  • Global Injectable Migraine Drugs Market Forecast by Value (2020-2024)
  • Global Migraine Drugs Market by Treatment Class (2019)
  • Global Abortive Migraine Drugs Market by Value (2015-2019)
  • Global Abortive Migraine Drugs Market Forecast by Value (2020-2024)
  • Global Preventative Migraine Drugs Market by Value (2015-2019)
  • Global Preventative Migraine Drugs Market Forecast by Value (2020-2024)
  • Global Migraine Drugs Market by Regions (2019)
  • North America Migraine Drugs Market by Value (2015-2019)
  • North America Migraine Drugs Market Forecast by Value (2020-2024)
  • North America Migraine Drugs Market by Region (2019)
  • The U.S. Migraine Drugs Market by Value (2015-2019)
  • The U.S. Migraine Drugs Market Forecast by Value (2020-2024)
  • Europe Migraine Drugs Market by Value (2015-2019)
  • Europe Migraine Drugs Market Forecast by Value (2020-2024)
  • Asia Pacific Migraine Drugs Market by Value (2015-2019)
  • Asia Pacific Migraine Drugs Market Forecast by Value (2020-2024)
  • ROW Migraine Drugs Market by Value (2015-2019)
  • ROW Migraine Drugs Market Forecast by Value (2020-2024)
  • Global Female Population (2015-2019)
  • Global Cigarette Consumption (2014-2018)
  • Global Pharmaceutical R&D Spending (2015-2019)
  • Global GDP Per Capita (2014-2018)
  • Global Healthcare Spending Per Capita (2014-2018)
  • Global Pharmaceutical and Biotech M&A (2015-2019)
  • Novartis AG Net Sales and Net Income (2015-2019)
  • Novartis AG Net Sales by Segments (2019)
  • Novartis AG Net Sales by Regions (2019)
  • Merck and Co. Sales and Net Income (2015-2019)
  • Merck and Co. Sales by Segments (2019)
  • Merck and Co. Sales by Regions (2019)
  • Amgen AG Total Revenue and Net Income (2015-2019)
  • Amgen AG Total Revenue by Divisions (2019)
  • Amgen AG Total Revenue by Regions (2019)
  • Eli Lilly and Company Revenue and Net Income (2015-2019)
  • Eli Lilly and Company Revenue by Divisions (2019)
  • Eli Lilly and Company Revenue by Regions (2019)
  • Teva Pharmaceuticals Revenue and Net Loss (Income) (2015-2019)
  • Teva Pharmaceuticals Revenue by Regions (2019)
  • Lundbeck Revenue and Profit (2015-2019)
  • Lundbeck Revenue by Regions (2019)

List of Tables

  • Difference Between Episodic and Chronic Migraine
  • Stages of Migraine
  • Global Share of Adults Experiencing Stress During COVID-19 (2020)
  • Progressing CGRP - Targeting Drug Pipeline
  • Branded Acute Treatment for Episodic Migraine
  • Key Players - Revenue Comparison (2019)
  • Key Players - R&D Expenditure Comparison
  • Key Players - Market Capitalization Comparison (2020)
  • Key Players - The U.S. CGRP Drugs for Episodic Migraine Market Penetration Forecast (2019-2023)
  • Key Players - The U.S. CGRP Drugs for Chronic Migraine Market Share Forecast (2019-2023)
Back to Top